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缩略词 英文全称 中文词义 
LC Lung cancer 肺癌 
NSCLC Non-small cell lung cancer 非小细胞肺癌 
SCLC Small cell lung cancer 小细胞肺癌 
EGF Epidermal growth factor 表皮生长因子 
EGFR Epidermal growth factor receptor 表皮生长因子受体 
TKI Tyrosine kinase inhibitor 酪氨酸激酶抑制剂 
ALK Anaplastic lymphoma kinase 间变性淋巴瘤激酶 
DEL19 Deletion in exon 19  19 外显子缺失 
L858R Point mutation at 858 position 858 位点点突变 




PD-1 Programmed cell death 1 程序细胞死亡受体 1 
VEGF Vascular endothelial growth factor 血管内皮生长因子 
PD-L1 Programmed cell death 1 ligand 1 程序细胞死亡配体 1 
ASCO American Society of Clinical Oncology 美国肿瘤学会 
ESMO European Society for Medical Oncology 欧洲肿瘤内科学会 
FDA Food and Drug Administration 美国食品药物监察
局 
CR Complete remission 完全缓解 




























两种主要敏感突变 19 外显子缺失突变与 21 外显子点突变（Del19 与 L858R）的
患者应用 TKI 治疗后临床获益有明显差别，而相应的分子机制至今仍未阐明。本
课题旨在分析比较 NSCLC 两种突变患者外周血全 miRNA 表达差异，筛选验证特异
的具有表达差异的 miRNA,探讨其信息通路和调节靶基因，从而阐明不同突变点
临床获益不同的分子基础，而且为临床预测更好的治疗效果提供有效的生物标志
物。我们利用 miRNA 芯片比较两组突变患者外周血中全 miRNA 获得 79 个差异表
达的 miRNA，其中 76 个在 Del19 突变患者中高表达，3 个 miRNA 为低表达。进一
步筛选代表性特异miRNA在44例NSCLC患者外周血中以q-PCR验证显示与miRNA























Lung cancer is the leading cause of cancer related death worldwide. 
Non-small-cell lung cancer (NSCLC) which consists of heterogeneous classes of 
tumors represents approximately 85% of all new lung cancer diagnoses. Smoking 
remains important while air pollution becomes more and more severe. Most patients 
are diagnosed with advanced-stage for inadequate prevention awareness and unclear 
symptoms and so on. Although the best way to cure lung cancer is surgery, few 
patients could really benefit from it due to reason listed above. Classical 
chemotherapy offers limited benefit while suffering complex adverse effects. Based 
on recognition of driver mutations, treatment paradigm for NSCLC patients has been 
shifted. Accurate staging of the cancer is required to determine the optimal 
management strategy, which includes surgery, radiochemotherapy, immunotherapy 
and targeted approaches with anti-angiogenic monoclonal antibodies or tyrosine 
kinase inhibitors if tumours harbour oncogene mutations. Several of these driver 
mutations have been identified (for example, in epidermal growth factor receptor 
(EGFR) and anaplastic lymphoma kinase (ALK), and therapy continues to advance to 
tackle acquired resistance problems.Patients could get clearly better benefit with less 
adverse effects. However, recently exon 19 deletion mutation (Del19) of epidermal 
growth factor receptor (EGFR) clearly shows better clinical benefit over single-point 
substitution mutation L858R in exon 21 (L858R). The aim of this study was to 
investigate the difference by analyzing the expression of plasma microRNAs of 
NSCLC patients with EGFR mutation Del19 or L858R. MiRNA microarray of plasma 
from patients’ blood identified 79 mapped, network-eligible miRNAs (fold > 5), of 
which 76 were up regulated and 3 were down. Among analysis, MYC, Argonaute2 
(AGO2), Y-box binding protein 1 (YBX1), cyclin E1 (CCNE1) were involved in 
organismal abnormalities and cancer. Our findings provide information on the 
epigenetic signature of the two major sensitive mutations among NSCLC and add to 
the understanding of mechanisms underlying the different outcomes. 
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肺癌是各类癌症中 相关死亡人数最多的恶性肿瘤。据美国在 2017 年 1 月最
新发布数据显示，肺癌死亡率和增长率在各类癌症中居首位。世界卫生组织发布
的癌症报告指出，2012 年我国男性癌症死亡人数高达 1，425，700 人，其中肺
癌占比最高，达 29.5%；女性癌症总死亡人数 779,550，肺癌占 22.5%。 
以上数据充分说明了现实形势的严峻以及挑战的艰巨。因此，肺癌防治研究
非常重要。 





































































































临床分非小细胞肺癌（non-small cell lung cancer,NSCLC）和小细胞肺癌
(small cell lung cancer,SCLC)。非小细胞肺癌又分三类：鳞状细胞癌(squamous 























































































1.6.1 X 线与 CT 
大多数肺癌都可由此诊断。中心型早期 X 线或不易看出。若肿块阻塞支气管，
可能出现肺炎征象。再度增大可能造成肺不张。再大，可出现肺门阴影。由于纵



















力。周围型肺癌 X 线表现较典型，但 CT 可以发现 X 线较易遗漏的早期灶。同理，
对与周边联系，具体侵犯范围等的信息也可一并提供。此外，胸部 CT 还可以对
肺部病灶进行三维重建，更清晰地显示早期肺癌的边缘、密度、对脏层胸膜的侵
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